402 related articles for article (PubMed ID: 12907009)
21. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
Lin YC; Chang HK; Wang CH; Chen JS; Liaw CC
Anticancer Drugs; 2000 Sep; 11(8):617-21. PubMed ID: 11081452
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.
Végran F; Boidot R; Coudert B; Fumoleau P; Arnould L; Garnier J; Causeret S; Fraise J; Dembélé D; Lizard-Nacol S
Br J Cancer; 2009 Oct; 101(8):1357-64. PubMed ID: 19755993
[TBL] [Abstract][Full Text] [Related]
23. Prospects with docetaxel in the treatment of patients with breast cancer.
Marty M; Extra JM; Cottu PH; Espié M
Eur J Cancer; 1997 Aug; 33 Suppl 7():S26-9. PubMed ID: 9486101
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer.
Suzuma T; Sakurai T; Yoshimura G; Umemura T; Tamaki T; Naito Y
Anticancer Drugs; 2000 Aug; 11(7):569-71. PubMed ID: 11036960
[TBL] [Abstract][Full Text] [Related]
25. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
[TBL] [Abstract][Full Text] [Related]
26. [Intra-arterial infusion chemotherapy with docetaxel for locally advanced breast cancer and inflammatory breast cancer].
Doi K; Ohchi T; Kudo S; Takahashi M; Sakamoto T; Ochiai T; Sakae T; Ishihara A
Gan To Kagaku Ryoho; 2000 Oct; 27(12):1823-5. PubMed ID: 11086421
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients.
Park S; Shimizu C; Shimoyama T; Takeda M; Ando M; Kohno T; Katsumata N; Kang YK; Nishio K; Fujiwara Y
Breast Cancer Res Treat; 2006 Sep; 99(1):9-17. PubMed ID: 16752223
[TBL] [Abstract][Full Text] [Related]
28. Predictive cancer genomics--what do we need?
Brenton JD; Caldas C
Lancet; 2003 Aug; 362(9381):340-1. PubMed ID: 12907001
[No Abstract] [Full Text] [Related]
29. [A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy].
Oura S; Tanino H; Yoshimasu T; Sakurai T; Nakamura T; Kokawa Y; Matsuyama K; Naito Y
Gan To Kagaku Ryoho; 2001 Apr; 28(4):511-4. PubMed ID: 11329786
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients.
Kurosumi M; Tabei T; Suemasu K; Inoue K; Kusawake T; Sugamata N; Higashi Y
Oncol Rep; 2000; 7(5):945-8. PubMed ID: 10948319
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
van Oosterom AT
Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564
[TBL] [Abstract][Full Text] [Related]
34. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
Fumoleau P; Chevallier B; Kerbrat P; Krakowski Y; Misset JL; Maugard-Louboutin C; Dieras V; Azli N; Bougon N; Riva A; Roche H
Ann Oncol; 1996 Feb; 7(2):165-71. PubMed ID: 8777173
[TBL] [Abstract][Full Text] [Related]
35. PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy.
Chen YZ; Xue JY; Chen CM; Yang BL; Xu QH; Wu F; Liu F; Ye X; Meng X; Liu GY; Shen ZZ; Shao ZM; Wu J
Cancer Chemother Pharmacol; 2012 Nov; 70(5):637-44. PubMed ID: 22903535
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
[TBL] [Abstract][Full Text] [Related]
37. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer.
Egawa C; Miyoshi Y; Takamura Y; Taguchi T; Tamaki Y; Noguchi S
Int J Cancer; 2001 Jul; 95(4):255-9. PubMed ID: 11400119
[TBL] [Abstract][Full Text] [Related]
38. Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice.
Veitia R; Bissery MC; Martinez C; Fellous A
Br J Cancer; 1998 Oct; 78(7):871-7. PubMed ID: 9764577
[TBL] [Abstract][Full Text] [Related]
39. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.
Estévez LG; Cuevas JM; Antón A; Florián J; López-Vega JM; Velasco A; Lobo F; Herrero A; Fortes J
Clin Cancer Res; 2003 Feb; 9(2):686-92. PubMed ID: 12576436
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
